CN119033822A - 用于抑制癫痫发作的组合物和方法 - Google Patents

用于抑制癫痫发作的组合物和方法 Download PDF

Info

Publication number
CN119033822A
CN119033822A CN202411196564.7A CN202411196564A CN119033822A CN 119033822 A CN119033822 A CN 119033822A CN 202411196564 A CN202411196564 A CN 202411196564A CN 119033822 A CN119033822 A CN 119033822A
Authority
CN
China
Prior art keywords
subject
mice
bacteria
seizure
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411196564.7A
Other languages
English (en)
Chinese (zh)
Inventor
E·萧
J·矢野
H·王
C·奥尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN119033822A publication Critical patent/CN119033822A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202411196564.7A 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法 Pending CN119033822A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662436711P 2016-12-20 2016-12-20
US62/436,711 2016-12-20
US201762447992P 2017-01-19 2017-01-19
US62/447,992 2017-01-19
CN201780086503.7A CN110325196B (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法
PCT/US2017/067548 WO2018119048A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780086503.7A Division CN110325196B (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法

Publications (1)

Publication Number Publication Date
CN119033822A true CN119033822A (zh) 2024-11-29

Family

ID=62627881

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411196564.7A Pending CN119033822A (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法
CN201780086503.7A Active CN110325196B (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780086503.7A Active CN110325196B (zh) 2016-12-20 2017-12-20 用于抑制癫痫发作的组合物和方法

Country Status (7)

Country Link
US (3) US11129858B2 (https=)
EP (1) EP3558329B1 (https=)
JP (1) JP7166280B2 (https=)
CN (2) CN119033822A (https=)
AU (1) AU2017382197B2 (https=)
CA (1) CA3047397A1 (https=)
WO (1) WO2018119048A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017382197B2 (en) 2016-12-20 2022-12-01 The Regents Of The University Of California Compositions and methods for inhibiting seizures
CA3066189A1 (en) * 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
CA3112135A1 (en) * 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
EP3856212A1 (en) * 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
WO2020076043A1 (ko) * 2018-10-08 2020-04-16 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
EP4166149A4 (en) * 2020-06-12 2024-12-18 Morinaga Milk Industry Co., Ltd. COMPOSITION IMPROVING MITOCHONDRIAL FUNCTION
CN113367328B (zh) * 2021-06-11 2023-02-21 无锡市人民医院 一种调节肠道菌群和能量代谢的多阶段生酮饮食配方
AU2022315538A1 (en) * 2021-07-20 2024-02-08 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders
WO2023001368A1 (en) * 2021-07-20 2023-01-26 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP3536328B1 (en) * 2013-02-22 2021-10-27 The Regents of The University of California Food or beverage product, or probiotic composition, comprising lactobacillus johnsonii 456
KR101445243B1 (ko) * 2014-03-28 2014-09-29 서울대학교산학협력단 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
EA201792547A1 (ru) * 2015-05-21 2018-04-30 Иеда Рисеч Энд Девелопмент Ко. Лтд. Популяции бактерий для стимуляции состояния здоровья
KR102534545B1 (ko) * 2015-05-22 2023-05-18 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
AU2017382197B2 (en) 2016-12-20 2022-12-01 The Regents Of The University Of California Compositions and methods for inhibiting seizures
US20220184084A1 (en) 2019-03-18 2022-06-16 The Regents Of The University Of California Compositions and methods for treating cushing's disease

Also Published As

Publication number Publication date
WO2018119048A1 (en) 2018-06-28
US12364717B2 (en) 2025-07-22
AU2017382197A1 (en) 2019-07-04
JP7166280B2 (ja) 2022-11-07
EP3558329B1 (en) 2024-01-31
US20220184144A1 (en) 2022-06-16
AU2017382197B2 (en) 2022-12-01
EP3558329A4 (en) 2020-07-22
EP3558329A1 (en) 2019-10-30
CN110325196B (zh) 2024-08-27
CA3047397A1 (en) 2018-06-28
EP3558329C0 (en) 2024-01-31
US20200384037A1 (en) 2020-12-10
JP2020502281A (ja) 2020-01-23
US20240238350A1 (en) 2024-07-18
CN110325196A (zh) 2019-10-11
US11129858B2 (en) 2021-09-28
US11883441B2 (en) 2024-01-30

Similar Documents

Publication Publication Date Title
CN110325196B (zh) 用于抑制癫痫发作的组合物和方法
JP7798785B2 (ja) 代謝の健康を改善するための細菌株を含む組成物
US12292445B2 (en) Methods of selecting subjects for treatment with metabolomic modulators
US20210128641A1 (en) Compositions and methods for treating skin and mucous membrane diseases
US8668906B2 (en) Lactobacillus plantarum strains as hypocholesterolemic agents
JP2018513196A (ja) マイクロバイオーム制御因子及び関連するその使用
US20250064882A1 (en) Postbiotic compositions and methods
EP4108260A1 (en) Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension
JPWO2019092896A1 (ja) アッカーマンシア・ムシニフィラ増殖材
US20220265733A1 (en) Compositions comprising bacterial strains
TWI740057B (zh) 乳雙歧桿菌gkk2之活性物質、含其之組合物及其促進長壽之用途
WO2020226683A1 (en) Compositions and methods for promoting healthy neural development in an unborn baby
WO2025038777A2 (en) Probiotics and methods to reduce appetite
EP3976026A2 (en) Compositions and methods for modulating cognitive behavior
US20250295709A1 (en) Postbiotic preparation for preventing or treating obesity
TW202027768A (zh) 包含細菌品系之組成物
WO2026096387A1 (en) Probiotics and methods to reduce weight
JP7738992B2 (ja) アルツハイマー病様症状緩和剤
JP2003238423A (ja) 血中コレステロール低下剤および血中コレステロール低下飲食品
WO2023102170A1 (en) Compositions and methods for inhibiting seizures
WO2026006209A1 (en) Compositions including n-acetyl-d-glucosamine (glcnac) as a prebiotic agent against multiple oral diseases
WO2025250747A1 (en) Gut microbiome-derived metabolite(s) promote skeletal muscle adaptation to exercise
NZ760637B2 (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination